Conformational Studies Using Second Derivative UV-Vis Absorption Spectroscopy

Significance of the Topic

Monoclonal antibodies (mAbs) have become cornerstone therapeutics in oncology and immune disorders. With original mAbs reaching patent expiry, biosimilars emerge as cost-effective alternatives. Demonstrating structural comparability and stability between innovator and biosimilar versions is critical for regulatory approval and ensuring therapeutic efficacy and safety.

Study Objectives and Overview

This study aimed to compare the conformational stability of rituximab innovator and biosimilar products using second derivative UV-Vis absorption spectroscopy. By monitoring aromatic amino acid microenvironments, the work evaluates whether both mAb forms exhibit equivalent structural responses to chemical denaturation.

Methodology

Sample preparation involved dissolving rituximab innovator and biosimilar in 20 mM Tris-HCl buffer (pH 6.0) at 500 mg/mL. Denaturation profiles were generated by incubating samples with guanidine hydrochloride (GdnHCl) concentrations from 0 to 6 M. Free L-phenylalanine, L-tyrosine, and L-tryptophan standards were prepared in water for spectral reference. High-resolution absorbance spectra (240–350 nm, 0.5 nm interval) were recorded at room temperature in a 1 cm pathlength quartz cuvette. Second derivative spectra were computed via the Savitzky-Golay algorithm and interpolated by cubic spline to 0.01 nm resolution for detailed peak analysis.

Instrumentation

• Agilent Cary 60 UV-Vis spectrophotometer with xenon flash lamp design
• 3 mL quartz cuvette, 1 cm path length
• Agilent Cary WinUV software for data acquisition and processing

Results and Discussion

Second derivative spectra resolved individual aromatic residue signals, notably the negative peak at ~291 nm corresponding to tryptophan. Denaturation induced by increasing GdnHCl led to systematic red shifts of this peak for both innovator and biosimilar forms, indicating similar unfolding behavior. A quantitative comparison of the a/b ratio, derived from tyrosine (λ~288 and λ~283 nm) and tryptophan (λ~294 and λ~291 nm) bands, showed an increase from ~1.05 under native conditions to higher values upon denaturation. Both mAb variants exhibited matching a/b profiles across all GdnHCl concentrations, confirming equivalent exposure of aromatic side chains and comparable higher-order structure.

Benefits and Practical Applications

• Second derivative UV-Vis spectroscopy is nondestructive, reagent-free, and rapid, allowing sample recovery for orthogonal analyses.
• It provides detailed insight into microenvironmental changes of aromatic residues, supplementing traditional methods like CD, fluorescence, and HPLC.
• As an accessible, robust technique, it can be implemented in QC labs for routine biosimilarity assessments and forced-degradation studies.

Future Trends and Opportunities

Integration of advanced UV-Vis derivative analysis with high-throughput robotic sampling may accelerate biosimilar screening. Coupling spectral data with machine learning algorithms could enhance pattern recognition of subtle conformational variants. Expanding applications to multi-domain proteins and antibody-drug conjugates will broaden the technique’s utility in biologics development.

Conclusion

The Agilent Cary 60 UV-Vis spectrophotometer, combined with second derivative absorption analysis, effectively distinguished structural unfolding behaviors of innovator and biosimilar rituximab. Both products demonstrated highly comparable aromatic residue environments and denaturation profiles, supporting their conformational equivalence. This accessible approach offers a valuable tool for biosimilarity evaluation and protein stability studies.

References

1. Scott A., Wolchok J., Old L. Antibody therapy of cancer. Nat. Rev. Cancer. 2012;12:278–287.
2. Udpa N., Million R. Monoclonal antibody biosimilars. Nat. Rev. Drug Discov. 2016;15:13–14.
3. Pace C.N., Scholtz J.M. Measuring the conformational stability of a protein. In Protein Structure: A Practical Approach; Oxford University Press: New York, 1997; pp. 299–321.
4. Zheng K., Bantog C., Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. mAbs. 2011;3(6):568–576.
5. Levine R., Federici M. Quantitation of aromatic residues in proteins: model compounds for second-derivative spectroscopy. Biochemistry. 1982;21:2600–2606.
6. Mach H., Middaugh C.R. Simultaneous monitoring of the environment of tryptophan, tyrosine, and phenylalanine residues in proteins by near-ultraviolet second-derivative spectroscopy. Anal. Biochem. 1994;222:323–331.
7. Agilent Technologies. Comparison of Biosimilar and Innovator Monoclonal Antibody Rituximab Using the Agilent 1260 Infinity Bio-inert LC System and Agilent OpenLAB Match Compare Software. Application Note 5991-4920EN.
8. Ragone R., Colonna G., et al. Determination of tyrosine exposure in proteins by second-derivative spectroscopy. Biochem. 1984;23(8):1871–1875.
9. Katayama D., Nayar R., et al. Solution behavior of a novel type 1 interferon, interferon-τ. J. Pharma. Sci. 2005;94:2703–2715.